Published in Infect Control Hosp Epidemiol on December 20, 2011
Reduced vancomycin susceptibility and staphylococcal cassette chromosome mec (SCCmec) type distribution in methicillin-resistant Staphylococcus aureus bacteraemia. J Antimicrob Chemother (2012) 0.96
Derivation and validation of clinical prediction rules for reduced vancomycin susceptibility in Staphylococcus aureus bacteraemia. Epidemiol Infect (2012) 0.77
Effects of vancomycin versus nafcillin in enhancing killing of methicillin-susceptible Staphylococcus aureus causing bacteremia by human cathelicidin LL-37. Eur J Clin Microbiol Infect Dis (2016) 0.77
Impact of Time to Appropriate Therapy on Mortality in Patients with Vancomycin-Intermediate Staphylococcus aureus Infection. Antimicrob Agents Chemother (2016) 0.75
Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst (1959) 94.48
Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data. Med Care (2005) 30.41
The impact of confounder selection criteria on effect estimation. Am J Epidemiol (1989) 13.34
Clinical practice guidelines by the infectious diseases society of america for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children. Clin Infect Dis (2011) 11.49
Influence of vancomycin minimum inhibitory concentration on the treatment of methicillin-resistant Staphylococcus aureus bacteremia. Clin Infect Dis (2008) 8.58
High-dose vancomycin therapy for methicillin-resistant Staphylococcus aureus infections: efficacy and toxicity. Arch Intern Med (2006) 7.56
Relationship of MIC and bactericidal activity to efficacy of vancomycin for treatment of methicillin-resistant Staphylococcus aureus bacteremia. J Clin Microbiol (2004) 6.65
The impact of methicillin resistance in Staphylococcus aureus bacteremia on patient outcomes: mortality, length of stay, and hospital charges. Infect Control Hosp Epidemiol (2005) 5.86
Accessory gene regulator group II polymorphism in methicillin-resistant Staphylococcus aureus is predictive of failure of vancomycin therapy. Clin Infect Dis (2004) 4.29
Relationship between vancomycin MIC and failure among patients with methicillin-resistant Staphylococcus aureus bacteremia treated with vancomycin. Antimicrob Agents Chemother (2008) 4.21
Inappropriate use of bivariable analysis to screen risk factors for use in multivariable analysis. J Clin Epidemiol (1996) 4.02
Vancomycin MIC creep in non-vancomycin-intermediate Staphylococcus aureus (VISA), vancomycin-susceptible clinical methicillin-resistant S. aureus (MRSA) blood isolates from 2001-05. J Antimicrob Chemother (2007) 3.93
Increased vancomycin MICs for Staphylococcus aureus clinical isolates from a university hospital during a 5-year period. J Clin Microbiol (2006) 3.34
An association between reduced susceptibility to daptomycin and reduced susceptibility to vancomycin in Staphylococcus aureus. Clin Infect Dis (2006) 2.98
A multicenter study evaluating the current strategies for isolating Staphylococcus aureus strains with reduced susceptibility to glycopeptides. J Clin Microbiol (2006) 2.74
Vancomycin in vitro bactericidal activity and its relationship to efficacy in clearance of methicillin-resistant Staphylococcus aureus bacteremia. Antimicrob Agents Chemother (2007) 2.42
Fluoroquinolones and the risk for methicillin-resistant Staphylococcus aureus in hospitalized patients. Emerg Infect Dis (2003) 2.06
Fitness cost of SCCmec and methicillin resistance levels in Staphylococcus aureus. Antimicrob Agents Chemother (2004) 1.97
Microbiological effects of prior vancomycin use in patients with methicillin-resistant Staphylococcus aureus bacteraemia. J Antimicrob Chemother (2007) 1.61
Comparison of detection methods for heteroresistant vancomycin-intermediate Staphylococcus aureus, with the population analysis profile method as the reference method. J Clin Microbiol (2010) 1.57
Limitations of vancomycin in the management of resistant staphylococcal infections. Clin Infect Dis (2007) 1.49
Fluoroquinolone-resistant Pseudomonas aeruginosa: assessment of risk factors and clinical impact. Am J Med (2006) 1.47
Susceptibility relationship between vancomycin and daptomycin in Staphylococcus aureus: facts and assumptions. Lancet Infect Dis (2009) 1.29
Spontaneous deletion of the methicillin resistance determinant, mecA, partially compensates for the fitness cost associated with high-level vancomycin resistance in Staphylococcus aureus. Antimicrob Agents Chemother (2008) 1.28
Nosocomial methicillin-resistant Staphylococcus aureus (MRSA) bacteremia in Taiwan: mortality analyses and the impact of vancomycin, MIC = 2 mg/L, by the broth microdilution method. BMC Infect Dis (2010) 1.26
Daptomycin bactericidal activity and correlation between disk and broth microdilution method results in testing of Staphylococcus aureus strains with decreased susceptibility to vancomycin. Antimicrob Agents Chemother (2006) 1.25
Trends in antimicrobial resistance in health care-associated pathogens and effect on treatment. Clin Infect Dis (2006) 1.23
Investigation of reduced susceptibility to glycopeptides among methicillin-resistant Staphylococcus aureus isolates from patients in Ireland and evaluation of agar screening methods for detection of heterogeneously glycopeptide-intermediate S. aureus. J Clin Microbiol (2007) 1.20
Investigating the association between antibiotic use and antibiotic resistance: impact of different methods of categorising prior antibiotic use. Int J Antimicrob Agents (2006) 1.12
Simultaneous carriage of multiple genotypes of Staphylococcus aureus in children. J Med Microbiol (2010) 1.11
Predictors of high vancomycin MIC values among patients with methicillin-resistant Staphylococcus aureus bacteraemia. J Antimicrob Chemother (2008) 1.08
Correlation between vancomycin and daptomycin MIC values for methicillin-susceptible and methicillin-resistant Staphylococcus aureus by 3 testing methodologies. Diagn Microbiol Infect Dis (2010) 1.02
Colonization with multiple Staphylococcus aureus strains among patients in European intensive care units. Infect Control Hosp Epidemiol (2009) 0.87
Coadministration of oral levofloxacin with agents that impair its absorption: potential impact on emergence of resistance. Int J Antimicrob Agents (2005) 0.80
Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America guidelines for developing an institutional program to enhance antimicrobial stewardship. Clin Infect Dis (2006) 14.63
Systematic review: opioid treatment for chronic back pain: prevalence, efficacy, and association with addiction. Ann Intern Med (2007) 5.68
The prevalence of fluoroquinolone resistance mechanisms in colonizing Escherichia coli isolates recovered from hospitalized patients. Clin Infect Dis (2010) 5.34
Absence of cross-reactivity between sulfonamide antibiotics and sulfonamide nonantibiotics. N Engl J Med (2003) 5.09
Clinical and microbiological outcomes of serious infections with multidrug-resistant gram-negative organisms treated with tigecycline. Clin Infect Dis (2008) 3.56
SHEA guideline for management of healthcare workers who are infected with hepatitis B virus, hepatitis C virus, and/or human immunodeficiency virus. Infect Control Hosp Epidemiol (2010) 3.44
Drug tolerance in replicating mycobacteria mediated by a macrophage-induced efflux mechanism. Cell (2011) 3.42
Systematic review and cost analysis comparing use of chlorhexidine with use of iodine for preoperative skin antisepsis to prevent surgical site infection. Infect Control Hosp Epidemiol (2010) 3.08
Fluoroquinolone utilization in the emergency departments of academic medical centers: prevalence of, and risk factors for, inappropriate use. Arch Intern Med (2003) 3.06
Association of dopamine agonist use with impulse control disorders in Parkinson disease. Arch Neurol (2006) 3.02
The effect of a primary care practice-based depression intervention on mortality in older adults: a randomized trial. Ann Intern Med (2007) 2.84
Risk factors and clinical impact of Klebsiella pneumoniae carbapenemase-producing K. pneumoniae. Infect Control Hosp Epidemiol (2009) 2.73
SHEA/APIC guideline: infection prevention and control in the long-term care facility, July 2008. Infect Control Hosp Epidemiol (2008) 2.35
Psychotropic medication use among Medicaid-enrolled children with autism spectrum disorders. Pediatrics (2008) 2.32
Differences in the epidemiological characteristics and clinical outcomes of pandemic (H1N1) 2009 influenza, compared with seasonal influenza. Infect Control Hosp Epidemiol (2010) 2.29
Hepatitis C virus seropositivity in organ donors and survival in heart transplant recipients. JAMA (2006) 2.26
Diabetes, depression, and death: a randomized controlled trial of a depression treatment program for older adults based in primary care (PROSPECT). Diabetes Care (2007) 2.23
Antibiotics, acne, and Staphylococcus aureus colonization. Arch Dermatol (2011) 2.22
Molecular epidemiological analysis of Escherichia coli sequence type ST131 (O25:H4) and blaCTX-M-15 among extended-spectrum-β-lactamase-producing E. coli from the United States, 2000 to 2009. Antimicrob Agents Chemother (2012) 2.17
Incidence and risk factors for herpes zoster among patients with inflammatory bowel disease. Clin Gastroenterol Hepatol (2006) 2.16
Surveillance definitions of infections in long-term care facilities: revisiting the McGeer criteria. Infect Control Hosp Epidemiol (2012) 2.15
Why is long-term therapy required to cure tuberculosis? PLoS Med (2007) 2.03
Phenotypic and genotypic characterization of fecal Escherichia coli isolates with decreased susceptibility to fluoroquinolones: results from a large hospital-based surveillance initiative. J Infect Dis (2006) 1.96
Long term effect of depression care management on mortality in older adults: follow-up of cluster randomized clinical trial in primary care. BMJ (2013) 1.91
Risk factors for fluconazole-resistant Candida glabrata bloodstream infections. Arch Intern Med (2009) 1.86
Surveillance cultures for detection of methicillin-resistant Staphylococcus aureus: diagnostic yield of anatomic sites and comparison of provider- and patient-collected samples. Infect Control Hosp Epidemiol (2009) 1.85
Longitudinal trends in fluoroquinolone resistance among Enterobacteriaceae isolates from inpatients and outpatients, 1989-2000: differences in the emergence and epidemiology of resistance across organisms. Clin Infect Dis (2004) 1.83
Impact of inadequate initial antimicrobial therapy on mortality in infections due to extended-spectrum beta-lactamase-producing enterobacteriaceae: variability by site of infection. Arch Intern Med (2005) 1.82
Imipenem resistance among pseudomonas aeruginosa isolates: risk factors for infection and impact of resistance on clinical and economic outcomes. Infect Control Hosp Epidemiol (2006) 1.76
Recommendations for metrics for multidrug-resistant organisms in healthcare settings: SHEA/HICPAC Position paper . Infect Control Hosp Epidemiol (2008) 1.73
Longitudinal trends in antimicrobial susceptibilities across long-term-care facilities: emergence of fluoroquinolone resistance. Infect Control Hosp Epidemiol (2005) 1.71
Stroke and conversion to high risk in children screened with transcranial Doppler ultrasound during the STOP study. Blood (2004) 1.66
Integrated management of type 2 diabetes mellitus and depression treatment to improve medication adherence: a randomized controlled trial. Ann Fam Med (2012) 1.64
The preventability of ventilator-associated events. The CDC Prevention Epicenters Wake Up and Breathe Collaborative. Am J Respir Crit Care Med (2015) 1.64
Reemergence of gram-negative health care-associated bloodstream infections. Arch Intern Med (2006) 1.63
Depression, cardiovascular disease, diabetes, and two-year mortality among older, primary-care patients. Am J Geriatr Psychiatry (2005) 1.62
"Equal" contributions and credit: an emerging trend in the characterization of authorship. Ann Epidemiol (2010) 1.57
SHEA/APIC Guideline: Infection prevention and control in the long-term care facility. Am J Infect Control (2008) 1.56
Use of the internet to enhance infectious disease surveillance and outbreak investigation. Biosecur Bioterror (2006) 1.49
Child care center exclusion policies and directors' opinions on the use of antibiotics. Infect Control Hosp Epidemiol (2010) 1.48
Fluoroquinolone-resistant Pseudomonas aeruginosa: assessment of risk factors and clinical impact. Am J Med (2006) 1.47
Patient ethnicity and the identification and active management of depression in late life. Arch Intern Med (2005) 1.47
Risk factors for disseminated candidiasis in children with candidemia. Pediatr Infect Dis J (2004) 1.45
Comparison of prior authorization and prospective audit with feedback for antimicrobial stewardship. Infect Control Hosp Epidemiol (2014) 1.45
Identification of optimal combinations for empirical dual antimicrobial therapy of Pseudomonas aeruginosa infection: potential role of a Combination Antibiogram. Infect Control Hosp Epidemiol (2006) 1.45
Represcription of penicillin after allergic-like events. J Allergy Clin Immunol (2004) 1.44
Evaluation of mannitol salt agar, CHROMagar Staph aureus and CHROMagar MRSA for detection of meticillin-resistant Staphylococcus aureus from nasal swab specimens. J Med Microbiol (2007) 1.44
Comparison of unit-specific and hospital-wide antibiograms: potential implications for selection of empirical antimicrobial therapy. Infect Control Hosp Epidemiol (2006) 1.42
The surgery clerkship: an opportunity for preclinical credentialing in urinary catheterization. Am J Surg (2012) 1.40
Risk factors for increasing multidrug resistance among extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella species. Clin Infect Dis (2005) 1.39
Body mass index, waist circumference and waist to hip ratio and change in sex steroid hormones: the Massachusetts Male Ageing Study. Clin Endocrinol (Oxf) (2006) 1.38
Household transmission of meticillin-resistant Staphylococcus aureus and other staphylococci. Lancet Infect Dis (2012) 1.38
Automated laboratory reporting of infectious diseases in a climate of bioterrorism. Emerg Infect Dis (2003) 1.37
One-year results of the Think Health! study of weight management in primary care practices. Obesity (Silver Spring) (2011) 1.37
Association between fluoroquinolone resistance and mortality in Escherichia coli and Klebsiella pneumoniae infections: the role of inadequate empirical antimicrobial therapy. Clin Infect Dis (2005) 1.35
Risk factors for and outcomes of bloodstream infection caused by extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella species in children. Pediatrics (2005) 1.33
Antidepressant studies in Parkinson's disease: a review and meta-analysis. Mov Disord (2005) 1.32
Risk factors for fluoroquinolone resistance in nosocomial Escherichia coli and Klebsiella pneumoniae infections. Arch Intern Med (2002) 1.32
Fluoroquinolone-resistant Escherichia coli carriage in long-term care facility. Emerg Infect Dis (2005) 1.32
Effectiveness of an HIV/STD risk-reduction intervention for adolescents when implemented by community-based organizations: a cluster-randomized controlled trial. Am J Public Health (2010) 1.31
Impact of freezing on the future utility of archived surveillance culture specimens. Infect Control Hosp Epidemiol (2007) 1.29
Prevalence of CTX-M beta-lactamases in Philadelphia, Pennsylvania. J Clin Microbiol (2009) 1.27
A systematic review of quasi-experimental study designs in the fields of infection control and antibiotic resistance. Clin Infect Dis (2005) 1.22
A 65-kilobase pathogenicity island is unique to Philadelphia-1 strains of Legionella pneumophila. J Bacteriol (2003) 1.18
Public reporting of health care-associated surveillance data: recommendations from the healthcare infection control practices advisory committee. Ann Intern Med (2013) 1.16
Mycobacterium chelonae-abscessus complex associated with sinopulmonary disease, Northeastern USA. Emerg Infect Dis (2011) 1.16
Improving disease reporting by clinicians: the effect of an internet-based intervention. J Public Health Manag Pract (2007) 1.15
Age of diagnosis among Medicaid-enrolled children with autism, 2001-2004. Psychiatr Serv (2010) 1.14
Impact of pediatric vaccination with pneumococcal conjugate vaccine on the risk of bacteremic pneumococcal pneumonia in adults. Vaccine (2005) 1.13
Colonization with extraintestinal pathogenic Escherichia coli among nursing home residents and its relationship to fluoroquinolone resistance. Antimicrob Agents Chemother (2004) 1.13
Is there cross-reactivity between penicillins and cephalosporins? Am J Med (2006) 1.13
Fluoroquinolone-resistant Escherichia coli in the long-term care setting. Am J Med (2006) 1.12
Investigating the association between antibiotic use and antibiotic resistance: impact of different methods of categorising prior antibiotic use. Int J Antimicrob Agents (2006) 1.12
Extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella species: risk factors for colonization and impact of antimicrobial formulary interventions on colonization prevalence. Infect Control Hosp Epidemiol (2002) 1.12
Limiting the emergence of extended-spectrum Beta-lactamase-producing enterobacteriaceae: influence of patient population characteristics on the response to antimicrobial formulary interventions. Infect Control Hosp Epidemiol (2006) 1.11
Specificity of ertapenem susceptibility screening for detection of Klebsiella pneumoniae carbapenemases. J Clin Microbiol (2009) 1.11
Stockpiling drugs for an avian influenza outbreak: examining the surge in oseltamivir prescriptions during heightened media coverage of the potential for a worldwide pandemic. Infect Control Hosp Epidemiol (2009) 1.08
The association of health literacy with adherence and outcomes in moderate-severe asthma. J Allergy Clin Immunol (2013) 1.08